

This item is the archived peer-reviewed author-version of:

Gene expression-based biodosimetry for radiological incidents : assessment of dose and time after radiation exposure

Reference:

Macaeva Elina, Mysara Mohammed, De Vos Winnok, Baatout Sarah, Quintens Roel.- Gene expression-based biodosimetry for radiological incidents : assessment of dose and time after radiation exposure
International journal of radiation biology - ISSN 0955-3002 - 95:1(2018), p. 64-75
Full text (Publisher's DOI): <https://doi.org/10.1080/09553002.2018.1511926>
To cite this reference: <https://hdl.handle.net/10067/1534010151162165141>

1 **Gene expression-based biodosimetry for radiological incidents:**
2 **assessment of dose and time after radiation exposure**

3

4 Ellina Macaeva^{1,2}, Mohamed Mysara¹, Winnok H. De Vos^{2,3}, Sarah
5 Baatout^{1,2}, Roel Quintens^{1#}

6

7 *¹Interdisciplinary Biosciences Group, Belgian Nuclear Research Centre, SCK•CEN,*
8 *Mol, Belgium*

9 *²Department of Molecular Biotechnology, Ghent University, Ghent, Belgium*

10 *³Department of Veterinary Sciences, University of Antwerp, Antwerp, Belgium*

11 *#Corresponding author: Roel Quintens, Boeretang 200, B-2400 Mol, Belgium. E-mail:*
12 *roel.quintens@sckcen.be. Phone: +32(0)14332837.*

13 Ellina Macaeva is a PhD student at the Radiobiology Unit of SCK•CEN working on
14 transcriptional radiation biomarkers.

15 Mohamed Mysara is a post-doctoral fellow in bioinformatics at the Belgian Nuclear Research
16 Centre.

17 Winnok De Vos (PhD Bioscience Engineering) is research professor at Antwerp University and
18 guest professor at Ghent University. He specialises in cell-centered research, with particular
19 focus on the role of the cell nucleus in accelerated aging diseases. To this end, he relies on a
20 multidisciplinary cocktail of techniques, including genome editing and deep coverage
21 microscopy.

22 Sarah Baatout is head of the Radiobiology Unit at the Belgian Nuclear Research Centre, guest
23 professor at Gent University and maître de conférence at University of Namur

24 Roel Quintens (PhD) is a senior scientist in the Radiobiology Unit at the Belgian Nuclear
25 Research Centre. Dr. Quintens coordinates two research lines: (i) effects of prenatal irradiation
26 on embryonic brain development, and (ii) identification of novel transcriptional radiation
27 biomarkers.

1 Gene expression-based biodosimetry for radiological incidents: 2 assessment of dose and time after radiation exposure

3 **Purpose:** In order to ensure efficient use of medical resources following a
4 radiological incident, there is an urgent need for high-throughput time-efficient
5 biodosimetry tools.

6 In the present study, we tested the applicability of a gene
7 expression signature for the prediction of exposure dose as well as the time
8 elapsed since irradiation. **Materials and methods:** We used whole blood
9 samples from seven healthy volunteers as calibration samples (X-ray doses: 0,
10 25, 50, 100, 500, 1000, and 2000 mGy; time points: 8, 12, 24, 36 and 48 h) and
11 samples from seven other individuals as 'blind samples' (20 samples in total).

12 **Results:** Gene expression values normalized to the reference gene without
13 normalization to the unexposed controls were sufficient to predict doses with a
14 correlation coefficient between the true and the predicted doses of 0.86.

15 Importantly, we could also classify the samples according to the time since
16 exposure with a correlation coefficient between the true and the predicted time
17 point of 0.96. Because of the dynamic nature of radiation-induced gene
18 expression, this feature will be of critical importance for adequate gene
19 expression-based dose prediction in a real emergency situation. **Conclusions:**

20 Our results represent an important advancement in the application of gene
21 expression for biodosimetry purposes.

22 **Keywords:** biodosimetry; gene expression; radiation; qRT-PCR array; time point
23 prediction; dose prediction

24 **Running title:** Gene expression-based biodosimetry

25 **Number of words:** 8 782

26 **Introduction**

27 Biodosimetry is the dose estimation after exposure to ionizing radiation by means of
28 changes in biological endpoints, or biomarkers. In the case of large-scale radiological
29 accidents, when physical dosimetry is not available for all the individuals at risk of
30 exposure, these biomarkers could be used to identify individual exposure cases. In such
31 situations triage decisions have to be undertaken as soon as possible in order to split the

1 exposed subjects into different categories, depending on their exposure dose and
2 radiosensitivity (Etherington et al. 2011). This kind of triage will allow focusing the
3 medical staff and facilities only on those subjects in need of urgent medical assistance
4 (Etherington et al. 2011).

5 As of yet, the gold standard method in biodosimetry is the detection of dicentric
6 chromosomes in peripheral blood lymphocytes (dicentric chromosome assay or DCA)
7 (International Atomic Energy Agency 2011). Besides its sensitivity to doses down to 20
8 mGy when scoring a few thousands metaphases (Lloyd et al. 1992), this method has
9 many other advantages, such as a high specificity to ionizing radiation, the possibility to
10 detect partial body exposure and the possibility of exposure assessment even months
11 after irradiation (International Atomic Energy Agency 2011). However, DCA is low in
12 throughput: it is time-consuming, laborious and requires well-trained personnel for
13 scoring. In 2010, the total capacity of European Union laboratories specialized in
14 biodosimetry for DCA was estimated to be 1493 samples in the triage mode and 187
15 samples in the full mode per week, excluding the 48 h needed for lymphocyte culturing
16 (Wojcik et al. 2010). This would be insufficient in case of a large-scale emergency with
17 thousands of potentially irradiated subjects. Several automated systems allowing for
18 faster dicentric scoring have been developed so far (Gruel et al. 2013; De Amicis et al.
19 2014; Garty et al. 2015), and several studies demonstrated the possibility of scoring a
20 limited number of cells (20-50) for fast triage purposes (Beinke et al. 2013; Oestreicher
21 et al. 2017). A simplification of dicentric scoring can also be achieved with the
22 application of telomere and centromere fluorescence *in situ* hybridization – the
23 technique which allows to simultaneously stain telomeres and centromeres (M'Kacher et
24 al. 2015). FISH-based translocation analysis is also the only validated biodosimetry

1 method allowing dose assessment years after actual exposure (Hall J et al. 2017), but
2 this does not offer an advantage for emergency triage.

3 A promising new approach for biodosimetry that offers superior time-efficiency (Abend
4 et al. 2016), is the analysis of changes in gene expression levels. Several genes, which
5 respond to radiation exposure have been studied using different methodological
6 approaches, such as whole genome microarray methods (Dressman et al. 2007; Fachin
7 et al. 2007; Paul and Amundson 2008; Boldt et al. 2012; Knops et al. 2012; Macaeva et
8 al. 2016) or quantitative PCR (Joiner et al. 2011; Kabacik et al. 2011; Manning et al.
9 2013; Tucker et al. 2014; Brzoska and Kruszewski 2015). Most of the identified genes
10 are known to be regulated by p53 (e.g. *MDM2* (Levine et al. 1997), *DDB2* (Hwang BJ
11 et al. 1999), *FDXR* (Hwang PM et al. 2001), *PCNA* (Xu and Morris 1999), *GADD45A*
12 (Hollander et al. 1993), *RPS27L* (He and Sun 2007), *SESNI* (Velasco-Miguel et al.
13 1999)), and are involved in canonical p53-mediated pathways such as cell cycle
14 regulation, DNA damage repair and apoptosis. Because some of them are induced in
15 isolated peripheral blood cells after exposure to doses as low as 5-25 mGy (Knops et al.
16 2012; Riecke et al. 2012a; Manning et al. 2013; Nosel et al. 2013), it can be stated that
17 in terms of sensitivity to low doses gene expression equals the DCA method. As a
18 result, the development of a biodosimetry gene signature and associated assays which
19 can be configured as devices suitable for low-cost, “point-of-care” measurements make
20 an appealing strategy (Bregues et al. 2010; Huang et al. 2011; Joiner et al. 2011).
21 Recently, we used microarrays to analyze the transcriptional response of human
22 peripheral blood mononuclear cells (PBMCs) exposed *ex vivo* to radiation doses of 0.0,
23 0.1, and 1.0 Gy and observed that many differentially expressed genes were also
24 alternatively transcribed/spliced in response to radiation (Macaeva et al. 2016). We

1 thereby identified a signature of genes and exons that showed high performance in dose
2 prediction (Macaeva et al. 2016).

3 One of the main difficulties in using changes in gene expression as a biomarker of
4 exposure is the highly dynamic and transient nature of the signal. The expression of
5 every single gene following radiation exposure is affected not only by the dose, but also
6 by the time, and the kinetics of expression is different for every gene (Manning et al.
7 2013). This means that knowledge of the time span between exposure and
8 measurement is pivotal for correct dose prediction. Using a signature of genes rather
9 than one single gene may therefore allow assessing the time after exposure based on the
10 combination of their expression profiles.

11 In addition, finding the right methodological approach to monitor gene expression as
12 early as possible following exposure is also important because the signal is lost within
13 days (Hall et al. 2017). Possible solutions to this include immediate snap freezing of
14 blood in liquid nitrogen or dry ice, which might be challenging in field conditions, or
15 addition of special whole blood preservation buffers (Schwochow et al. 2012), which
16 would also solve the problem of effective preservation of easily-degradable RNA.

17 Another challenge of using whole blood for gene expression studies is the heterogeneity
18 of blood cells. About 99% of blood cells are red blood cells, including immature
19 reticulocytes, which contain high levels of globin mRNA accounting for ~ 70% of all
20 mRNA in whole blood. This can compromise the detection of other specific mRNAs
21 from white blood cells (Field et al. 2007). Although qPCR is less affected by globin
22 mRNA contamination, this parameter is highly important for such techniques as
23 microarrays (Liu et al. 2006) and next generation sequencing (Schwochow et al. 2012).

24 In the present study we firstly compared RNA quality from blood samples processed
25 using different RNA extraction methods. Next, the potential of a gene expression assay

1 using a customized qRT-PCR array to predict both dose and time after exposure was
2 investigated. Genes were chosen based on our previous study, taking into consideration
3 the different sensitivities of single exons. Besides, we included three genes (*PF4*,
4 *GNG11* and *CCR4*) which were up-regulated in response to low-dose exposure (0.05
5 Gy) and down-regulated after a higher dose (1 Gy) (El-Saghire et al. 2013).

6 **Materials and methods**

7 *Comparison of RNA extraction methods*

8 As a first step of the present study, the performance of two RNA extraction kits
9 specifically designed for RNA extraction from whole blood - QIAamp RNA Blood
10 Mini Kit (Qiagen, Hilden, Germany) and PAXgene Blood RNA Kit (PreAnalytiX,
11 Hombrechtikon, Switzerland) - was tested under different conditions (Figure 1).

12 Peripheral blood samples were collected from five healthy donors with informed
13 consent and ethical approval from the local SCK•CEN Ethics Committee. The
14 procedure was carried out in accordance with the ethical standards of the Helsinki
15 Declaration of 1975, as revised in 2000.

16 [Figure 1 near here]

17 RNA extractions were performed following the manufacturer's instructions, unless
18 mentioned otherwise (see Figure 1 for details). RNA concentration was measured on a
19 Trinean Xpose instrument (Trinean, Gent-Brugge, Belgium) and the quality of total
20 RNA samples was assessed using Agilent 2100 Bioanalyser (Agilent Technologies,
21 Santa Clara, CA, USA) by calculating the RNA integrity number (RIN). RIN for a
22 sample is computed using several characteristics of an RNA electrophoregram trace, the
23 most important being the ratio of the area under the 18S and 28S rRNA peaks. Based on
24 the results each sample is assigned a value of 1 to 10, with 10 being the least degraded.

1 Globin mRNA contamination was assessed using qRT-PCR with primers specific to
2 *HBA1* and *HBB* genes using isolated PBMCs as a reference. PBMCs isolation was
3 performed as previously described in Macaeva et al. (2016). RNA extraction from
4 isolated PBMCs was performed using the RNeasy Mini Kit (Qiagen) following the
5 manufacturer's instructions.
6 cDNA synthesis was performed using the GoScript™ Reverse Transcription System
7 (Promega, Leiden, The Netherlands) with random hexamer primers. For each gene,
8 qRT-PCR reactions were run in duplicate using the MESA GREEN® qRT-PCR kit
9 (Eurogentec, Seraing, Belgium) on an Applied Biosystems® 7500 Real-Time PCR
10 instrument following the manufacturer's instructions. qRT-PCR data were analyzed by
11 7500 Software v2.0.6 and Microsoft Excel using the Pfaffl method (Pfaffl 2001). The
12 relative amount of transcript of the selected genes was normalized to *PGK1* and *HPRT1*
13 reference genes using the geometric mean of the threshold cycle (Ct) values of these
14 reference genes (Vandesompele et al. 2002).

15 ***Blood collection and in vitro irradiation***

16 Peripheral blood samples were collected in EDTA coated tubes from healthy donors
17 with informed consent and ethical approval from the local SCK•CEN Ethics
18 Committee. All procedures were carried out in accordance with the ethical standards of
19 the Helsinki Declaration of 1975, as revised in 2000. Half of the samples were used as
20 calibration samples, the other half was used as blind samples. Donor information can be
21 found in Table 1.

22 [Table 1 near here]

23 Each blood sample was collected in an EDTA-coated tube and aliquoted in either 5 ml
24 (calibration samples) or 2 ml (blind samples) tubes for irradiation. Calibration samples
25 were irradiated with 0, 25, 50, 100, 500, 1000, and 2000 mGy, after which the tubes

1 were placed on a rocking platform in an incubator at 37°C without CO₂ supply. The
2 irradiations were performed at room temperature with an Xstrahl machine (250 kV, 1.4
3 mm Cu + 3.8 mm Al filtration) at a dose rate of 0.14 Gy/min. At 8, 12, 24, 36 and 48 h
4 after irradiation a 1 ml aliquot was taken from each sample and used for RNA
5 extraction. The doses and fixation time points for blind samples were assigned
6 randomly and are given in Table 2.

7 [Table 2 near here]

8 ***RNA extraction, quantification and quality control***

9 The QIAamp RNA Blood Mini Kit was used to extract RNA from the blood samples
10 used in the biodosimetry part of the present study. All procedures were performed
11 following the manufacturer's instructions, unless stated otherwise. RNA concentration
12 was measured on a Trinean Xpose instrument and the quality of total RNA samples
13 was assessed using Agilent 2100 Bioanalyser (Agilent Technologies, Santa Clara, CA,
14 USA). All samples had a RIN >8 and were therefore considered as suitable for further
15 processing.

16 ***Reverse transcription and qPCR***

17 cDNA synthesis on the samples used for biodosimetry part of this study was performed
18 using the RT² First Strand Kit (Qiagen) following the manufacturer's instructions.

19 qPCRs were run using custom RT² Profiler PCR Arrays and the RT² SYBR Green
20 Mastermix (Qiagen) on an ABI7500 Fast instrument (Applied Biosystems). Standard
21 96-well plate-format arrays were used, including 25 genes of interest, four reference
22 genes (*HPRT1*, *PGK1*, *GAPDH* and *B2M*), a positive PCR control, a human genomic
23 DNA contamination control and a reverse transcription control. Each 96-well array
24 could therefore be used to run three samples. The list of genes present on the arrays is
25 provided in Supplementary table 1. Based on our previous results (Macaeva et al. 2016),

1 for the genes alternatively transcribed/spliced in response to irradiation, primers were
2 designed to target the most responsive exons (Supplementary table 1). qRT-PCR data
3 were analyzed using the dedicated software available at:

4 [http://www.qiagen.com/be/shop/genes-and-pathways/data-analysis-center-overview-
page/custom-rt2-pcr-arrays-data-analysis-center/](http://www.qiagen.com/be/shop/genes-and-pathways/data-analysis-center-overview-
5 page/custom-rt2-pcr-arrays-data-analysis-center/)

6 After comparing the variability of expression (standard deviations of Ct values in 245
7 calibration samples) of the four reference genes, it was decided to use only *B2M* for
8 normalization. The obtained differences in threshold cycle (Δ Ct) values compared to
9 that of *B2M* were used to train the prediction models. Relative expression levels were
10 tested for statistical significance using a 2-way ANOVA with Bonferroni *post-hoc* test.

11 ***Classification***

12 Two models were built to predict both the radiation dose and time point of each blind
13 sample based on the gene expression profiles. Two separate datasets were used for
14 training and testing. For training the models, the data acquired from seven donors
15 (calibration samples, Table 1) were used, while for testing we used the data of seven
16 different donors (blind samples, Table 1). Training both models consisted of five
17 consecutive steps, 1) identifying the genes most likely responsible for the prediction of
18 the radiation doses and time points (i.e. feature identification), 2) selecting the most
19 informative features (i.e. feature selection), 3) building both models using the classifiers
20 available (i.e. model training), 4) testing the models with a database unexposed to the
21 training step (i.e. model testing), 5) selecting the best performing model for both
22 problems (i.e. model nomination).

23 Feature (gene) identification was performed in our previous study (Macaeva et al.
24 2016). Both dose and time point were treated as a regression variable ranging from 0
25 mGy to 2000 mGy and 0 h to 48 h, respectively. Importantly, the testing dataset was not

1 only constructed from new subjects but also new intermediate doses such as 30, 60, 400,
2 700, 900, 1200 and 1600 mGy not used for training the model were included. This is
3 particularly important to illustrate the independency of the model from the set of
4 training instances.

5 Secondly, we attempted to perform a feature selection step, important to reduce the
6 complexity and to increase the accuracy of the model. To investigate if all features were
7 necessary for the predictive model, we used the WEKA software implementation to
8 assess the importance of all attributes. Interestingly, however, performing the principle
9 component analysis illustrated the necessity for all features to describe 95% of the
10 variance within the training dataset (data not shown). Consequently all features were
11 included for training both models using a wide range of classifiers available in WEKA
12 (Hall et al. 2009).

13 Different classification and regression models were considered including Support
14 Vector Machines (SVM), linear regression, Multi-Layer Perceptron (a neural network),
15 nearest neighbour, and three decision tree models: M5Base (implementing base routines
16 for generating M5 Model trees and rules), decision stump, Fast decision tree learner, as
17 implemented in WEKA (Hall et al. 2009). Next, each of the trained classifiers was
18 tested using the test dataset, during the fourth step (model testing). To select the optimal
19 classifier, we trained and tested various models. We reported for each classifier Pearson
20 correlation coefficient and the relative absolute error (RAE) calculated for dose
21 prediction as following:

$$22 \quad RAE_{Dose} = \sum_{i=1}^n |x_i - y_i| / \sum_{i=1}^n |z - y_i|$$

23 where x_i is the predicted dose, y_i is the true dose, z is the average of x values, for every
24 n cases.

25 For time point prediction RAE was calculated as following:

1

2 $RAE_{Time} = \sum_{i=1}^n |x_i - y_i| / \sum_{i=1}^n |z - y_i|$

3 where x_i is the predicted time point, y_i is the true time point, z is the average of x
4 values, for every n cases.

5 Finally, we nominated the best performing model for each case (predicting the radiation
6 doses and time points) achieving the lowest mean absolute error whilst having the
7 highest correlation coefficient.

8 **Results**

9 *Optimization of RNA extraction protocols for emergency situations*

10 To optimize RNA extraction for emergency situations, different protocols were
11 compared and the total RNA content, integrity and contamination were quantified
12 (Figure 2).

13 [Figure 2 near here]

14 In this part of the study a few modifications of the standard protocols of two
15 commercially available kits were tested: PAXgene tubes, which are specifically
16 designed for direct collection of blood and preservation of RNA for up to 3 days at
17 room temperature and up to 50 months at -20°C and the QIAmp kit intended for
18 molecular biology applications. The PAXgene system showed consistently high yields
19 of high-quality RNA, in case blood was directly collected in PAXgene tubes (Figure 2,
20 Standard PAXgene protocol, Modified protocols 1 and 2). Alternatively, the option of
21 collecting the blood in standard EDTA-coated tubes followed by transfer into PAXgene
22 tubes was also explored (Figure 2, Modified protocol 3). This approach resulted in
23 extraction of high-quality RNA, although at lower yields compared to the standard
24 PAXgene procedure. Importantly, sufficient RNA of acceptable quality could also be
25 extracted from the blood samples which were frozen at -20°C and transferred into

1 PAXgene tubes after thawing (Figure 2, Modified protocol 4). Since the QIAmp
2 protocol does not allow processing of frozen blood, the options to modify the protocol
3 were limited (Modified protocol 5). Nevertheless, both tested protocols involving this
4 kit resulted in high yields of RNA of high quality (Figure 2, Modified protocol 5 and
5 QIAmp standard protocol). Also the possible contamination of RNA samples with
6 excessive globin mRNA was tested (Figure 2C). In this respect, the QIAmp kit clearly
7 outperformed PAXgene, showing low globin mRNA contamination comparable to
8 those obtained for isolated PBMCs, used as a reference in which no contamination was
9 to be expected.

10 ***Robust dose- and time-dependent response of the biodosimetric gene panel***

11 In order to identify the best endogenous controls consistently expressed across the
12 sample population, we compared the variability of expression of *PGK1*, *HPRT1*,
13 *GAPDH* and *B2M* as reference genes. The standard deviations of Ct values for *B2M*
14 were lower than those for *PGK1*, *HPRT1* and *GAPDH* (Supplementary table 2). Also
15 the differences between the minimal and maximal registered Ct values for *B2M* were
16 the lowest (~5 cycles difference compared to ~10 cycles for the other genes). Therefore,
17 in the subsequent analyses, the Ct values of target genes were normalized to *B2M*.
18 Blood samples from seven healthy volunteers exposed to X-ray doses ranging from 25
19 to 2000 mGy were used as calibration samples at five different time points following
20 exposure: 8, 12, 24, 36 and 48 hours. In total, expression levels of 25 genes were
21 assessed (Figure 3).

22 [Figure 3 near here]

23 Overall, we observed dose-dependent increases in gene expression (up to 22-fold in the
24 case of *FDXR*) for the majority of the genes, at all the different time points (Figure 3). It
25 was clear, however, that different genes had very different kinetics. For instance,

1 induction of *FDXR* peaked after 8 h (Figure 4A), while that of *DDB2* was stable up to
2 36 h after irradiation (Figure 4B). *TNFRSF10B* was stably induced up to 24 h, less so
3 after 36 h and no longer induced after 48 h (Figure 4C). Importantly, for many genes
4 (*FDXR, DDB2, TNFRSF10B, AEN, XPC, BAX, ASTN2, NDUFAF6, MAMDC4,*
5 *PHPT1, ASCC3, TRIAP1, LR5*) these changes were significant at least at one time point
6 after exposure to the lowest dose of 25 mGy. We also found, in agreement with
7 previous findings (Abend et al. 2016; Manning et al. 2013) that most genes showed a
8 plateau at doses above 1000 mGy at which no further induction could be observed.
9 However, some genes did not show any significant changes at all, e.g. *SESNI*, and the
10 genes previously identified as having opposite changes in response to low- and high-
11 dose radiation (*PF4, GNG11, CCR4*) (El-Saghire et al. 2013) (Figure 3).
12 Importantly, a time-dependent up-regulation in gene expression was seen for several
13 genes (Figure 3F, Figures 4D-F), particularly those involved in apoptosis (*AEN, BAX,*
14 *FDXR, TNFRSF10B*) and DNA damage repair (*ASCC3, DDB2, XPC*). This was most
15 evident after 48 h and suggested that even in unirradiated samples, cells were becoming
16 apoptotic over time. Some genes, like *CDKN1A* and *RPS27L* were induced in control
17 samples already after 12 h, which strongly affected the radiation response for these
18 genes at later time points. Nevertheless, we could still observe dose-dependent changes
19 in gene expression, even after 48 h although radiation-induced changes were in general
20 less outspoken at this time point. This may be, at least in part due to the fact that gene
21 expression was already induced in control samples.

22 [Figure 4 near here]

23 *Dose and time after exposure can be predicted from radiation-induced changes in*
24 *gene expression*

1 The ΔC_t values of all the calibration samples were used as the training dataset to build
2 the models for dose and time point prediction. Next, the selected model was used to
3 predict the dose and the time after exposure of the blind samples (Table 3 and Figures 5
4 and 6).
5 [Table 3 near here]
6 [Figure 5 near here]
7 For the dose prediction, the fast decision tree learner (implemented as REPTree in
8 WEKA) could achieve the highest Pearson correlation coefficient of 0.86 between the
9 true and the predicted doses with the lowest RAE of 42%. The merit of this classifier is
10 that it builds the decision based on the information gain and prunes the tree branches
11 using reduced-error pruning (with backfitting). Dose prediction was more accurate for
12 doses below 0.5 Gy (Pearson correlation 0.85) compared to higher doses (Pearson
13 correlation 0.55), probably resulting from the previously described plateau effect of the
14 gene expression response at doses above 1 Gy (Manning et al. 2013; Abend et al. 2016;
15 Manning et al. 2017). Although most of the genes were required to explain the
16 variability within the data, a set of four genes (*MDM2*, *FDXR*, *ASCC3* and *CDKN1A*)
17 was considered particularly important for dose prediction. For the time point prediction,
18 the M5Base decision tree classifier (implemented in WEKA as M5P) was able to
19 achieve a correlation coefficient between the true and the predicted time points of 0.96
20 (with lowest RAE of 28%). M5Base implements base routines for the generation of the
21 M5 model (Quinlan 1992; Wang and Witten 1997). It functions as a decision tree by
22 splitting the data into branches and leaves based on few parameters, but instead of
23 assigning the "time points" for each leaf, a linear regression function is calculated for
24 each leaf (enabling a continuous numeric prediction).

1 [Figure 6 near here]

2 The 48-h time point was the most difficult to predict with four predictions out of four
3 outside of the ± 4 h interval (Table 3). The most discriminative genes for time point
4 prediction were *AEN*, *ASCC3*, *CDKN1A*, *GNG11* and *CCR4*, although all genes were
5 necessary to describe the dissimilarity within the data.

6 In case of both dose and time point prediction using only the most important genes did
7 not result in significantly better model performance (data not shown). All three samples
8 misclassified according to the true dose were also misclassified according to the true
9 time point (Table 3).

10 Among the blood donors , one was a smoker, one recently stopped smoking and one
11 individual reported a recent infection. Prediction of the doses or time points for these
12 individuals was not particularly more problematic (Figure 7). Also, the median age of
13 donors whose blood was used for calibration samples (27 years) was lower than that of
14 the blind sample donors (54 years). Nevertheless dose prediction was still efficient
15 suggesting that age does not affect dose prediction.

16 [Figure 7 near here]

17 **Discussion**

18 Gene expression is emerging as a highly powerful readout for biodosimetry. Several
19 studies demonstrated the applicability of microarray technology for analyzing large sets
20 of transcripts for dose prediction for exposure to acute doses (Dressman et al. 2007;
21 Meadows et al. 2008; Paul and Amundson 2008; Macaeva et al. 2016). However, as
22 was demonstrated in a recent biodosimetry exercise, the analysis of a short list of genes,
23 or even one gene by means of qPCR technology, is far more straightforward and
24 cheaper compared to microarray analysis, while the accuracy of dose prediction is
25 essentially similar (Abend et al. 2016). Many of the genes included in our biodosimetry

1 panel were also previously tested by other groups (Riecke et al. 2012b; Manning et al.
2 2013; Tucker et al. 2014; Brzoska and Kruszewski 2015), suggesting their robustness as
3 radiation biomarkers. However, our panel composition is unique because we selected
4 the most radiation-sensitive exons of the respective genes for qRT-PCR analysis based
5 on our previous results (Macaeva et al. 2016). We used seven X-ray doses ranging from
6 25 mGy to 2 Gy to generate calibration samples. Moderately high doses of 1-2 Gy may
7 result in acute radiation syndrome, therefore the individuals receiving doses above this
8 threshold will benefit greatly from prompt treatment (Sullivan et al. 2013). However, in
9 case of a radiological accident, most victims would be exposed to much lower doses.
10 Although lower doses down to 100 mGy are not associated with immediate health
11 effects they might require medical follow-up due to the risk of long-term effects,
12 particularly cancer (UNSCEAR 2006). To add to that, the fears about the effects of
13 radiation and the uncertainty about the exposure doses may lead to further stress and
14 mental health effects, as has already happened after the Chernobyl and Fukushima
15 accidents (WHO 2006; Brumfiel 2013; Bromet 2014). In this respect, we believe that
16 assessment and communication of any radiation dose is important. As it is unlikely that
17 any single biodosimetry assay can be used as a stand-alone tool to meet the
18 requirements of throughput, time-efficiency and accuracy needed, it was suggested to
19 perform stepwise triage starting with assessment of less than or greater than a 2-Gy
20 dose, followed by a secondary high-throughput screening to further define individual
21 doses (Sullivan et al. 2013). Thus, a combination of high-throughput methods with high
22 accuracy in the low (e.g. gene expression), and the high dose ranges could prove to be
23 an ideal match for practical biodosimetry in emergency cases.
24 An important aspect that we have addressed in this study is the dynamic nature of the
25 gene expression response to radiation exposure which can have a major impact on

1 accurate dose prediction in cases when the exact time point of irradiation is not known.
2 Taking the example of *FDXR*, a gene often considered to be the most sensitive and
3 accurate gene biodosimeter (Abend et al. 2016; Manning et al. 2017; Hall et al. 2017;
4 O'Brien et al. 2018). In our experimental set-up, a ~5-fold up-regulation of *FDXR* could
5 indicate (i) the early (8-24 h), maximal response to a low dose of 100 mGy, (ii) the very
6 early (<8 h) sub-maximal response to a higher dose, or (iii) the late (>36 h) residual
7 response to a higher dose. This example shows that, no matter how sensitive, a single
8 gene cannot sufficiently predict the dose when there is no indication of the time elapsed
9 since exposure. In such a case, the combination of a panel of genes, each with their own
10 kinetics and amplitudes is needed. The same example also highlights that is pivotal to
11 take the time elapsed after exposure into consideration. The classification method used
12 in our study allowed to classify the samples according to the time elapsed since
13 exposure with high precision (errors ≤ 4 h). The importance of the time factor is also
14 highlighted by the fact that all three samples misclassified according to the true dose
15 were also misclassified according to the true time point. It is important to note,
16 however, that the gene expression kinetics might be different following *in vivo*
17 exposure. Thus, adaptation of our methodology for *in vivo* exposure situation may be
18 required. The possibility of using specific weighting factors for adaptation of *in vitro*
19 generated calibration curves for dose prediction of *in vivo* exposed blood samples from
20 radiotherapy patients was successfully explored in a recent biodosimetry exercise
21 (Abend et al. 2016). The potential of *FDXR* as radiation biomarker of *in vivo* exposures
22 was thoroughly investigated in a recent study by O'Brien and co-authors (O'Brien et al.
23 2018). This study demonstrated that the expression of this gene was significantly up-
24 regulated already at 2 h following a diagnostic CT-scan (low-dose exposure to 2.9-20.9
25 mGy dose to the blood) (O'Brien et al. 2018). The expression of *FDXR* was also

1 significantly up-regulated 24 h following the first fraction of radiotherapy treatment in
2 most patients involved in this study and its expression remained up-regulated during the
3 fractionated treatment (O'Brien et al. 2018). Importantly, no significant differences in
4 *FDXR* expression were found between *ex vivo* and *in vivo* irradiated samples from the
5 same patients (O'Brien et al. 2018).

6 In many studies published so far, fold changes in gene expression between irradiated
7 and control samples from the same subject were used (Kabacik et al. 2011; Riecke et al.
8 2012a; Manning et al. 2013). In a real large-scale emergency, such data will not be
9 available. Therefore, in the present study, we opted to use Δ Ct values compared to the
10 reference gene. This approach has been successfully applied in several exploratory
11 studies (Tucker et al. 2014; Brzoska and Kruszewski 2015), as well as in two recent
12 biodosimetry exercises (Abend et al. 2016; Manning et al. 2017).

13 For most of the studied genes we found a plateau in expression for high doses (1000 and
14 2000 mGy), which contributed to less precise dose prediction in the higher dose range
15 as exemplified by the lower correlation coefficient (CC = 0.55) compared to that of the
16 lower dose range (CC = 0.85). This may reflect a saturation of the response, but it might
17 also be the result of *in vitro* culture conditions. Indeed, similar findings have been
18 previously observed in other studies using *ex vivo* irradiated whole blood or cultured
19 blood cells (Manning et al. 2013; Ghandhi et al. 2015; Abend et al. 2016; Manning et al.
20 2017). In contrast, in experiments using *ex vivo* irradiated blood which was diluted
21 tenfold in RPMI culture medium, this effect was only observed at doses above 6 Gy
22 (Tucker et al. 2014), comparable to what was seen in whole body irradiated mice in a
23 study from the same group (Tucker et al. 2013). Similarly, in radiotherapy patients
24 undergoing total body irradiation several genes included in our panel (e.g. *CDKN1A*,

1 *FDXR*, and *PHPT1*) showed further up-regulation after 3.75 Gy compared to 1.25 Gy
2 (Paul et al. 2011).

3 In the present study, we opted for using undiluted blood for our experiments, to
4 interfere as little as possible with the samples as gene expression changes might be
5 affected by culture conditions, and more specifically by addition of fetal bovine serum
6 (Shahdadfar et al. 2005; Bieback et al. 2010). A similar approach as ours was used by
7 Manning and co-authors, showing 99% cell viability in blood samples incubated for 24
8 h at 37°C (Manning et al. 2013). In our study, an increase in expression with time,
9 especially at 36 and 48 h was seen for a number of genes involved in apoptosis,
10 suggesting an increase in the number of dying cells with time. This may have also
11 influenced the radiation-induced response of these genes, and therefore the dose
12 prediction. Nevertheless, we were able to accurately (absolute error ≤ 300 mGy) predict
13 the radiation doses of 6 out of 8 blind samples from the 36-h and 48-h time points.

14 *In vivo* irradiation experiments performed by Tucker and co-authors in mice confirmed
15 the possibility of dose prediction based on gene expression for at least 7 days after
16 exposure (Tucker et al. 2013). Whether the same is true in humans remains to be
17 investigated. Studies involving radiotherapy patients showed that prediction of *in vivo*
18 radiation dose using gene signatures was possible for at least 24 h following exposure
19 (Paul et al. 2011; Abend et al. 2016). Further *in vivo* validation of biodosimetric gene
20 signatures at longer time intervals is therefore warranted.

21 In our study, we did not address the effect of dose rate on gene expression. Several
22 studies addressing this issue were previously performed in total body irradiated mice
23 (Paul et al. 2015) and *ex vivo* irradiated human blood (3.1 mGy/min vs 1.03 Gy/min)
24 (Ghandhi et al. 2015). Overall, these studies showed that a significant number of genes
25 responded similarly to low dose rate and acute exposures. This was especially seen for

1 typical P53-regulated genes, many of which were also included in our gene panel,
2 although the amplitude of the response was sometimes higher after high dose rate
3 exposure. Interestingly, in both studies classification models could very efficiently
4 discriminate between low and high dose rate irradiated samples, showing that gene
5 signatures may be used to discriminate between acute and protracted exposures.

6 An important step for biodosimetric triage of casualties of a radiological accident is to
7 appropriately collect and preserve (blood) samples for further analysis. For gene
8 expression measurement the time elapsed from exposure to blood collection and sample
9 fixation is critical for correct dose estimation, as gene expression in non-frozen and
10 non-stabilized blood would still be subjected to change not only as a result of radiation
11 exposure, but also due to *ex vivo* incubation itself (Baechler et al. 2004). Several
12 approaches to solve this issue were previously tested. Brzoska and Kruszewski
13 extracted RNA for gene expression analysis from whole blood which was frozen and
14 stored at -75°C (Brzoska and Kruszewski 2015). In a real-life situation this approach
15 would, however, not be practical due to the lack of very low temperature freezers. An
16 alternative approach, tested during a recent RENEB biodosimetry exercise, includes the
17 addition of RNA stabilization reagents which protect RNA from degradation allowing
18 for sample storage and transportation at room temperature for several hours or even
19 days. However, this methodology still requires the availability of significant quantities
20 of such reagents at the accident site while the further processing of the samples might be
21 affected by transport conditions (Manning et al. 2017). Therefore, we tested the freezing
22 of whole blood at -20°C, which would allow blood preservation without any specific
23 equipment or reagents. Upon delivery to the biodosimetric laboratory, blood samples
24 would be thawed and transferred to PAXgene tubes, allowing for recovery of sufficient
25 RNA of acceptable quality. A recent biodosimetry exercise showed that dose prediction

1 accuracy using our qRT-PCR arrays is not affected by the differences in RNA
2 extraction methods, including those which result in high globin mRNA contamination
3 (Manning et al. 2017).

4 Taken together, in the present study, we proved the usefulness of a biosimetric panel
5 of genes in predicting both dose and time after *in vitro* exposure. Our results confirm
6 that the analysis of expression of these genes, which can be carried out in virtually any
7 laboratory possessing a qPCR instrument, can certainly provide sufficient information
8 for triage purposes in comparatively short amount of time. The validity of our
9 customized biosimetric qPCR arrays was recently confirmed in an interlaboratory
10 comparison exercise organized by RENEb (Manning et al. 2017). Although in this
11 exercise different experimental procedures, including different dose assessment
12 approach were used, we could still achieve good dose prediction (Manning et al. 2017),
13 confirming the flexibility and versatility of our method. We also suggest a method
14 allowing for further RNA extraction from blood samples stored at -20°C, which is the
15 most realistic for field conditions. Further research is needed to confirm the time- and
16 dose-wise validity and applicability of our signature for *in vivo* situation, as well as to
17 reveal the potential impact of confounding factors on the reliability of the gene
18 expression-based biosimetry.

19 **Disclosure of interest**

20 Authors declare no competing interests.

21 Acknowledgments. This study was supported by the *ad hoc* DoReMi funding (EU FP7, grant
22 number 249689). The authors wish to thank the SCK•CEN medical service staff for the help
23 with blood drawing, as well as all the blood donors involved in this study. Ellina Macaeva is a
24 recipient of a joint doctoral SCK•CEN/UGent grant.

25

1 Tables

Table 1. Donor information

Donor	Gender	Age	Smoking status	Recent viral/bacterial infection	Reference/blind sample
D1	Male	24	No	No	Reference
D2	Female	24	No	No	Reference
D3	Male	29	No	No	Reference
D4	Male	23	No	Yes	Reference
D5	Female	28	No	No	Reference
D6	Female	27	No	No	Reference
D7	Female	46	No	No	Reference
D8	Male	56	Recently stopped	No	Blind
D9	Male	58	No	No	Blind
D10	Male	54	No	No	Blind
D11	Male	49	No	No	Blind
D12	Male	40	No	No	Blind
D13	Male	56	Yes	No	Blind
D14	Male	30	No	Yes	Blind

2

Table 2. Information on doses and time points assigned to blind samples

Donor	Code	Dose, mGy	Time point, h
D8	B	0	8
D8	R	200	8
D8	P	900	12
D9	I	700	8
D9	C	60	12
D9	L	0	24
D10	S	1200	12
D10	A	30	24
D11	W	100	8
D11	F	1600	36
D11	M	0	48
D12	Q	60	36
D12	T	200	36
D12	G	2000	36
D13	Y	400	24
D13	U	400	48
D13	D	1200	48
D14	E	100	12
D14	J	0	24
D14	O	700	48

3

1
2
3

Table 3. Dose and time point prediction results for blind samples

Sample code (with remark)	True time point, h	Predicted time point, h	Error, h	True dose, mGy	Predicted dose, mGy	Error, mGy
A	24	23.3	-0.7	30	20	-10
B (ex-smoker)	8	9.5	+1.5	0	20	+20
C	12	10.2	-1.8	60	20	-40
D (smoker)	48	44.0	-4.0	1200	900	-300
E (infection)	12	8.9	-3.1	100	30	-70
F	36	39.6	+3.4	1600	1370	-230
G	36	43.2	+7.2	2000	1370	-630
I	8	4.5	-3.5	700	410	-290
J (infection)	24	22.1	-1.9	0	20	+20
L	24	15.5	-8.5	0	20	+20
M	48	42.7	-5.3	0	120	+120
O (infection)	48	43.9	-4.1	700	900	+200
P (ex-smoker)	12	14.0	+2.0	900	1370	+470
Q	36	39.0	+3.0	60	120	+60
R (ex-smoker)	8	10.5	+2.5	200	420	+220
S	12	18.4	+6.4	1200	420	-780
T	36	40.1	+4.1	200	120	-80
U (smoker)	48	41.0	-7.0	400	900	+500
W	8	10.0	+2.0	100	230	+130
Y (smoker)	24	21.4	-2.6	400	410	+10

Bold: time point predictions with more than 4 h difference from the true time point and dose predictions with more than 500 mGy difference from the true dose.

4

5 Figures

6 **Figure 1.** Schematic representation of the experimental procedures.

7

8 **Figure 2.** Comparison of RNA extraction protocols. A. Quantity of RNA extracted
9 following each protocol. Statistical comparison performed using two-tailed paired t-test.
10 In case two bars are mark with the same letter(s) the difference is not statistically
11 significant ($p > 0.05$), if the letters are different the difference between two conditions
12 is statistically significant. B. Quality of RNA extracted following each protocol.
13 Statistical comparison performed using two-tailed paired t-test. In case two bars are
14 mark with the same letter(s) the difference is not statistically significant ($p > 0.05$), if
15 the letters are different the difference between two conditions is statistically significant.

1 C. Levels of contamination of RNA extracted from whole blood samples with PAXgene
2 and QIAmp kits with excessive globin mRNA assessed as expression of α - and β -globin
3 coding genes. Statistical comparison performed using unpaired t test. SP – standard
4 protocol, MP – modified protocol. Bars represent the mean of five measurement, error
5 bars represent SD. **p < 0.005, ***p < 0.001.

6
7 **Figure 3. A-E.** Heatmaps showing the average of expression levels in seven donors
8 (relative to control samples per time point, \log_2 transformed) for all the 25 genes (shown
9 in rows) included in the qPCR arrays in response to exposure to different doses (shown
10 in columns) at five time points. F. Heatmap showing the relative expression levels in
11 sham-irradiated samples from seven donors relative to sham-irradiated samples at 8 h
12 for all the 25 genes (shown in rows) at five time points (shown in columns).

13
14 **Figure 4. A-C.** Changes in expression of *FDXR*, *DDB2* and *TNFRSF10B* relative to
15 sham-irradiated samples at 8 h time point. Bars represent the average of samples from
16 seven donors irradiated *in vitro* with doses from 0 to 2000 mGy and fixed at 5 time
17 points after exposure. **D-F.** Changes in expression of *FDXR*, *DDB2* and *TNFRSF10B*
18 relative to sham-irradiated samples per time point. Bars represent the average of
19 samples from seven donors irradiated *in vitro* with doses from 0 to 2000 mGy and fixed
20 at 5 time points after exposure.

21
22 **Figure 5.** The decision tree for the REPTree model built for dose prediction, ending
23 with 11 leaves (for each the dose prediction is calculated).

24
25 **Figure 6.** The decision tree for the M5Base model built for time point prediction,
26 ending with 23 leaves (for each a linear model named LM1-LM23 has been calculated).

27
28 **Figure 7.** Dose (A) and time point (B) prediction results for the blind samples. CC –
29 correlation coefficient.

Bibliography

- 1
2
- 3 Abend M, Badie C, Quintens R, Kriehuber R, Manning G, Macaeva E, Njima M,
4 Oskamp D, Strunz S, Moertl S et al. 2016. Examining Radiation-Induced In Vivo and In
5 Vitro Gene Expression Changes of the Peripheral Blood in Different Laboratories for
6 Biodosimetry Purposes: First RENEb Gene Expression Study. *Radiat Res.* 185(2):109-
7 123.
- 8 Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Moser K, Ortmann WA, Espe
9 KJ, Balasubramanian S, Hughes KM, Chan JP et al. 2004. Expression levels for many
10 genes in human peripheral blood cells are highly sensitive to ex vivo incubation. *Genes*
11 *Immun.* 5(5):347-353.
- 12 Beinke C, Barnard S, Boulay-Greene H, De Amicis A, De Sanctis S, Herodin F, Jones
13 A, Kulka U, Lista F, Lloyd D et al. 2013. Laboratory intercomparison of the dicentric
14 chromosome analysis assay. *Radiat Res.* 180(2):129-137.
- 15 Bieback K, Ha VA, Hecker A, Grassl M, Kinzibach S, Solz H, Sticht C, Kluter H,
16 Bugert P. 2010. Altered gene expression in human adipose stem cells cultured with fetal
17 bovine serum compared to human supplements. *Tissue Eng Part A.* 16(11):3467-3484.
- 18 Boldt S, Knops K, Kriehuber R, Wolkenhauer O. 2012. A frequency-based gene
19 selection method to identify robust biomarkers for radiation dose prediction. *Int J Radiat*
20 *Biol.* 88(3):267-276.
- 21 Brengues M, Paap B, Bittner M, Amundson S, Seligmann B, Korn R, Lenigk R,
22 Zenhausern F. 2010. Biodosimetry on small blood volume using gene expression assay.
23 *Health Phys.* 98(2):179-185.
- 24 Bromet EJ. 2014. Emotional consequences of nuclear power plant disasters. *Health*
25 *Phys.* 106(2):206-210.
- 26 Brumfiel G. 2013. Fukushima: Fallout of fear. *Nature.* 493(7432):290-293.
- 27 Brzoska K, Kruszewski M. 2015. Toward the development of transcriptional
28 biodosimetry for the identification of irradiated individuals and assessment of absorbed
29 radiation dose. *Radiat Environ Biophys.* 54(3):353-363.
- 30 De Amicis A, De Sanctis S, Di Cristofaro S, Franchini V, Regalbutto E, Mammana G,
31 Lista F. 2014. Dose Estimation Using Dicentric Chromosome Assay and Cytokinesis
32 Block Micronucleus Assay: Comparison between Manual and Automated Scoring in
33 Triage Mode. *Health Phys.* 106(6):787-797. English.
- 34 Dressman HK, Muramoto GG, Chao NJ, Meadows S, Marshall D, Ginsburg GS, Nevins
35 JR, Chute JP. 2007. Gene expression signatures that predict radiation exposure in mice
36 and humans. *PLoS Med.* 4(4):690-701. English.
- 37 Etherington G, Rothkamm K, Shutt AL, Youngman MJ. 2011. Triage, monitoring and
38 dose assessment for people exposed to ionising radiation following a malevolent act.
39 *Radiat Prot Dosimetry.* 144(1-4):534-539.
- 40 Fachin AL, Mello SS, Sandrin-Garcia P, Junta CM, Donadi EA, Passos GA, Sakamoto-
41 Hojo ET. 2007. Gene expression profiles in human lymphocytes irradiated in vitro with
42 low doses of gamma rays. *Radiat Res.* 168(6):650-665.
- 43 Field LA, Jordan RM, Hadix JA, Dunn MA, Shriver CD, Ellsworth RE, Ellsworth DL.
44 2007. Functional identity of genes detectable in expression profiling assays following
45 globin mRNA reduction of peripheral blood samples. *Clin Biochem.* 40(7):499-502.
- 46 Garty G, Bigelow AW, Repin M, Turner HC, Bian D, Balajee AS, Lyulko OV, Taveras
47 M, Yao YL, Brenner DJ. 2015. An automated imaging system for radiation
48 biodosimetry. *Microsc Res Tech.* 78(7):587-598.

1 Ghandhi SA, Smilenov LB, Elliston CD, Chowdhury M, Amundson SA. 2015.
2 Radiation dose-rate effects on gene expression for human biodosimetry. *BMC Med*
3 *Genomics*. 8:22.
4 Gruel G, Gregoire E, Lecas S, Martin C, Roch-Lefevre S, Vaurijoux A, Voisin P,
5 Voisin P, Barquinero JF. 2013. Biological dosimetry by automated dicentric scoring in a
6 simulated emergency. *Radiat Res*. 179(5):557-569.
7 Hall J, Jeggo PA, West C, Gomolka M, Quintens R, Badie C, Laurent O, Aerts A,
8 Anastasov N, Azimzadeh O et al. 2017. Ionizing radiation biomarkers in
9 epidemiological studies - An update. *Mutat Res*. 771:59-84.
10 Hall M, Frank E, Holmes G, Pfahringer B, Reutemann P, Witten I. 2009. The WEKA
11 Data Mining Software: An Update. *SIGKDD Explor Newsl*. 11(1):10-18.
12 He H, Sun Y. 2007. Ribosomal protein S27L is a direct p53 target that regulates
13 apoptosis. *Oncogene*. 26(19):2707-2716.
14 Hollander MC, Alamo I, Jackman J, Wang MG, McBride OW, Fornace AJ, Jr. 1993.
15 Analysis of the mammalian gadd45 gene and its response to DNA damage. *J Biol*
16 *Chem*. 268(32):24385-24393.
17 Huang TC, Paul S, Gong P, Levicky R, Kymissis J, Amundson SA, Shepard KL. 2011.
18 Gene expression analysis with an integrated CMOS microarray by time-resolved
19 fluorescence detection. *Biosens Bioelectron*. 26(5):2660-2665.
20 Hwang BJ, Ford JM, Hanawalt PC, Chu G. 1999. Expression of the p48 xeroderma
21 pigmentosum gene is p53-dependent and is involved in global genomic repair. *Proc Natl*
22 *Acad Sci U S A*. 96(2):424-428.
23 Hwang PM, Bunz F, Yu J, Rago C, Chan TA, Murphy MP, Kelso GF, Smith RA,
24 Kinzler KW, Vogelstein B. 2001. Ferredoxin reductase affects p53-dependent, 5-
25 fluorouracil-induced apoptosis in colorectal cancer cells. *Nat Med*. 7(10):1111-1117.
26 International Atomic Energy Agency. 2011. Cytogenetic Dosimetry: Applications in
27 Preparedness for and Response to Radiation Emergencies. EPR-biodosimetry.
28 Joiner MC, Thomas RA, Grever WE, Smolinski JM, Divine GW, Kanski AA, Auner
29 GW, Tucker JD. 2011. Developing point of care and high-throughput biological assays
30 for determining absorbed radiation dose. *Radiother Oncol*. 101(1):233-236.
31 Kabacik S, Mackay A, Tamber N, Manning G, Finnon P, Paillier F, Ashworth A,
32 Bouffler S, Badie C. 2011. Gene expression following ionising radiation: identification
33 of biomarkers for dose estimation and prediction of individual response. *Int J Radiat*
34 *Biol*. 87(2):115-129.
35 Knops K, Boldt S, Wolkenhauer O, Kriehuber R. 2012. Gene expression in low- and
36 high-dose-irradiated human peripheral blood lymphocytes: possible applications for
37 biodosimetry. *Radiat Res*. 178(4):304-312.
38 Levine SJ, Wu T, Shelhamer JH. 1997. Extracellular release of the type I intracellular
39 IL-1 receptor antagonist from human airway epithelial cells: differential effects of IL-4,
40 IL-13, IFN-gamma, and corticosteroids. *J Immunol*. 158(12):5949-5957.
41 Liu J, Walter E, Stenger D, Thach D. 2006. Effects of globin mRNA reduction methods
42 on gene expression profiles from whole blood. *J Mol Diagn*. 8(5):551-558.
43 Lloyd DC, Edwards AA, Leonard A, Deknudt GL, Verschaeve L, Natarajan AT,
44 Darroudi F, Obe G, Palitti F, Tanzarella C et al. 1992. Chromosomal aberrations in
45 human lymphocytes induced in vitro by very low doses of X-rays. *Int J Radiat Biol*.
46 61(3):335-343.
47 M'Kacher R, El Maalouf E, Terzoudi G, Ricoul M, Heidingsfelder L, Karachristou I,
48 Laplagne E, Hempel WM, Colicchio B, Dieterlen A et al. 2015. Detection and
49 automated scoring of dicentric chromosomes in nonstimulated lymphocyte prematurely

1 condensed chromosomes after telomere and centromere staining. *Int J Radiat Oncol*
2 *Biol Phys.* 91(3):640-649.

3 Macaeva E, Saeys Y, Tabury K, Janssen A, Michaux A, Benotmane MA, De Vos WH,
4 Baatout S, Quintens R. 2016. Radiation-induced alternative transcription and splicing
5 events and their applicability to practical biodosimetry. *Sci Rep.* 6:19251.

6 Manning G, Kabacik S, Finnon P, Bouffler S, Badie C. 2013. High and low dose
7 responses of transcriptional biomarkers in ex vivo X-irradiated human blood. *Int J*
8 *Radiat Biol.* 89(7):512-522.

9 Manning G, Macaeva E, Majewski M, Kriehuber R, Brzoska K, Abend M, Doucha-
10 Senf S, Oskamp D, Strunz S, Quintens R et al. 2017. Comparable dose estimates of
11 blinded whole blood samples are obtained independently of culture conditions and
12 analytical approaches. Second RENEb gene expression study. *Int J Radiat Biol.*
13 93(1):87-98.

14 Meadows SK, Dressman HK, Muramoto GG, Himburg H, Salter A, Wei ZZ, Ginsburg
15 G, Chao NJ, Nevins JR, Chute JP. 2008. Gene Expression Signatures of Radiation
16 Response Are Specific, Durable and Accurate in Mice and Humans. *PLoS One.* 3(4).
17 English.

18 Nosel I, Vaurijoux A, Barquinero JF, Gruel G. 2013. Characterization of gene
19 expression profiles at low and very low doses of ionizing radiation. *DNA Repair*
20 *(Amst).* 12(7):508-517.

21 O'Brien G, Cruz-Garcia L, Majewski M, Grepl J, Abend M, Port M, Tichy A, Sirak I,
22 Malkova A, Donovan E et al. 2018. FDXR is a biomarker of radiation exposure in vivo.
23 *Sci Rep.* 8(1):684.

24 Oestreicher U, Samaga D, Ainsbury E, Antunes AC, Baeyens A, Barrios L, Beinke C,
25 Beukes P, Blakely WF, Cucu A et al. 2017. RENEb intercomparisons applying the
26 conventional Dicentric Chromosome Assay (DCA). *Int J Radiat Biol.* 93(1):20-29.

27 Paul S, Amundson SA. 2008. Development of gene expression signatures for practical
28 radiation biodosimetry. *Int J Radiat Oncol Biol Phys.* 71(4):1236-1244.

29 Paul S, Barker CA, Turner HC, McLane A, Wolden SL, Amundson SA. 2011.
30 Prediction of In Vivo Radiation Dose Status in Radiotherapy Patients using Ex Vivo
31 and In Vivo Gene Expression Signatures. *Radiat Res.* 175(3):257-265. English.

32 Paul S, Smilenov LB, Elliston CD, Amundson SA. 2015. Radiation Dose-Rate Effects
33 on Gene Expression in a Mouse Biodosimetry Model. *Radiat Res.* 184(1):24-32.

34 Pfaffl MW. 2001. A new mathematical model for relative quantification in real-time
35 RT-PCR. *Nucleic Acids Res.* 29(9):e45.

36 Learning with Continuous Classes. 5th Australian Joint Conference on Artificial
37 Intelligence; 1992; Singapore.

38 Riecke A, Rufa CG, Cordes M, Hartmann J, Meineke V, Abend M. 2012a. Gene
39 expression comparisons performed for biodosimetry purposes on in vitro peripheral
40 blood cellular subsets and irradiated individuals. *Radiat Res.* 178(3):234-243.

41 Riecke A, Rufa CG, Cordes M, Hartmann J, Meineke V, Abend M. 2012b. Gene
42 Expression Comparisons Performed for Biodosimetry Purposes on In Vitro Peripheral
43 Blood Cellular Subsets and Irradiated Individuals. *Radiat Res.* 178(3):234-243. English.

44 Schwochow D, Serieys LE, Wayne RK, Thalmann O. 2012. Efficient recovery of whole
45 blood RNA--a comparison of commercial RNA extraction protocols for high-
46 throughput applications in wildlife species. *BMC Biotechnol.* 12:33.

47 Shahdadfar A, Fronsaldal K, Haug T, Reinholt FP, Brinchmann JE. 2005. In vitro
48 expansion of human mesenchymal stem cells: choice of serum is a determinant of cell
49 proliferation, differentiation, gene expression, and transcriptome stability. *Stem Cells.*
50 23(9):1357-1366.

1 Sullivan JM, Prasanna PG, Grace MB, Wathen LK, Wallace RL, Koerner JF, Coleman
2 CN. 2013. Assessment of biodosimetry methods for a mass-casualty radiological
3 incident: medical response and management considerations. *Health Phys.* 105(6):540-
4 554.

5 Tucker JD, Divine GW, Grever WE, Thomas RA, Joiner MC, Smolinski JM, Auner
6 GW. 2013. Gene expression-based dosimetry by dose and time in mice following acute
7 radiation exposure. *PLoS One.* 8(12):e83390.

8 Tucker JD, Joiner MC, Thomas RA, Grever WE, Bakhmutsky MV, Chinkhota CN,
9 Smolinski JM, Divine GW, Auner GW. 2014. Accurate gene expression-based
10 biodosimetry using a minimal set of human gene transcripts. *Int J Radiat Oncol Biol*
11 *Phys.* 88(4):933-939.

12 UNSCEAR 2006 Report. Volume I: Report to the General Assembly, Annex A:
13 Epidemiological studies of radiation and cancer. United Nations.

14 Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman
15 F. 2002. Accurate normalization of real-time quantitative RT-PCR data by geometric
16 averaging of multiple internal control genes. *Genome Biol.* 3(7):RESEARCH0034.

17 Velasco-Miguel S, Buckbinder L, Jean P, Gelbert L, Talbott R, Laidlaw J, Seizinger B,
18 Kley N. 1999. PA26, a novel target of the p53 tumor suppressor and member of the
19 GADD family of DNA damage and growth arrest inducible genes. *Oncogene.*
20 18(1):127-137.

21 Wang Y, Witten I. Induction of model trees for predicting continuous classes. 9th
22 European Conference on Machine Learning; 1997.

23 WHO. 2006. Health effects of the Chernobyl accident and special health care
24 programmes. Geneva: World Health Organization.

25 Wojcik A, Lloyd D, Romm H, Roy L. 2010. Biological dosimetry for triage of
26 casualties in a large-scale radiological emergency: capacity of the EU member states.
27 *Radiat Prot Dosimetry.* 138(4):397-401.

28 Xu J, Morris GF. 1999. p53-mediated regulation of proliferating cell nuclear antigen
29 expression in cells exposed to ionizing radiation. *Mol Cell Biol.* 19(1):12-20.

30